Relmada Therapeutics Inc (RLMD) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Relmada Therapeutics Inc stock $5.01, price $3.90, upside +28.4%, quality 50 out of 100. Rating: undervalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Show moreShow less
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Stock analysis
Relmada Therapeutics Inc (RLMD) currently trades at $3.90, while our model-based Fair Value estimate is $5.01, implying the stock looks roughly 22% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $3.76 (bear) to $6.25 (bull), the price of $3.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Relmada Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$57.4M in FY2025.
Key figures
Market cap $438M Small · EPS (TTM) $−0.9100 · Return on equity −55.7% · Return on assets (EBIT) −103% (5-year average) · Free cash flow −$45.8M · Net cash $3.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 4 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 28%, RLMD screens cheaper than that median.
Fair Value models
Bear$3.76Fair Value $5.01Bull$6.25
Price $3.90 · Upside +28.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA$4.42$5.89$7.3564
NCAV (Graham)$0.5400$0.8100$1.0152
All 2 models by family
Multiples
EV/EBITDA$4.42$5.89$7.3564
Asset-Based
NCAV (Graham)$0.5400$0.8100$1.0152
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, 2 officers or directors bought shares worth $1.7M, most recently on Sep 10, 2026. Buying cluster
BuySergio TraversaChief Executive Officer, Director2× since Dec 15, 2025: 227,500 shares, avg. $4.14$941,300Sep 10, 2026
BuyMaged ShenoudaChief Financial Officer2× since Dec 15, 2025: 211,665 shares, avg. $4.21$892,050Sep 10, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Relmada Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Above median
Fair Value upside+28.4% · Top 25%
Profitability
Return on assets−61.1% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Relmada Therapeutics Inc (RLMD) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $5.01 versus a price of $3.90, about +28% upside (undervalued).
What is the fair value of RLMD?
Our model-based fair value for Relmada Therapeutics Inc is $5.01 (as of Nov 8, 2026), built from audited fundamentals. The current price: $3.90.
What is the quality score of RLMD?
Relmada Therapeutics Inc has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Relmada Therapeutics Inc (RLMD)?
Our model-based price target is the fair value of $5.01 (as of Nov 8, 2026) from 2 valuation models. Cautious scenario $3.76, optimistic scenario $6.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Relmada Therapeutics Inc stock forecast for 2026?
Our models put fair value at $5.01, about +28% upside versus a price of $3.90 (undervalued). Cautious scenario $3.76, optimistic scenario $6.25. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Relmada Therapeutics Inc (RLMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Relmada Therapeutics Inc it is $5.01 per share (as of Nov 8, 2026), against a price of $3.90. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Relmada Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, RLMD trades below its calculated fair value: price $3.90, fair value $5.01, a gap of about +28% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RLMD?
No. The price is what the market pays today ($3.90); the fair value is what the company's own numbers justify ($5.01). For Relmada Therapeutics Inc the two are $1.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Relmada Therapeutics Inc worth?
The market values Relmada Therapeutics Inc at about $438M (market capitalisation, as of Nov 8, 2026). Per share that is $3.90; our models calculate a fair value of $5.01 per share.
What do the bullish and bearish scenarios say about RLMD?
Our models span a range for Relmada Therapeutics Inc: cautious scenario $3.76, base $5.01, optimistic $6.25 per share (as of Nov 8, 2026, price $3.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Relmada Therapeutics Inc (RLMD)?
Balance-sheet figures for Relmada Therapeutics Inc (as of Nov 8, 2026): return on equity −55.7%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is RLMD from its 52-week high?
Relmada Therapeutics Inc trades at $3.90, about 50% below its 52-week high of $7.86 and 49% above the low of $2.61 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.01 is for.
Which stocks are comparable to Relmada Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Relmada Therapeutics Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $3.90, calculated fair value $5.01 (+28%), Quality Score 50/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RLMD calculated?
We run Relmada Therapeutics Inc through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.01 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Relmada Therapeutics Inc currently trades 22% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Relmada Therapeutics Inc (RLMD)?
The closing price on Nov 6, 2026 was $3.90. Our model-based fair value is $5.01, about +28% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Relmada Therapeutics Inc right now?
Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Relmada Therapeutics Inc
How large is the market capitalisation of Relmada Therapeutics Inc (RLMD)?
The market capitalisation of Relmada Therapeutics Inc is $438M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Relmada Therapeutics Inc (RLMD)?
Earnings per share at Relmada Therapeutics Inc are $−0.9100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Relmada Therapeutics Inc (RLMD)?
The return on equity (ROE) of Relmada Therapeutics Inc is −55.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Relmada Therapeutics Inc (RLMD)?
On an EBIT basis the return on assets of Relmada Therapeutics Inc is −103% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Relmada Therapeutics Inc (RLMD) generate?
The free cash flow of Relmada Therapeutics Inc is −$45.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Relmada Therapeutics Inc (RLMD) hold?
Relmada Therapeutics Inc holds more cash than debt, $3.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Relmada Therapeutics Inc in the live analysis
One click puts Relmada Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
